Influx Healthtech Limited is a Mumbai-based, healthcare focused company specialising in contract manufacturing. Since its inception in 2020, the company has established itself as a reliable Contract Development and Manufacturing Organization (CDMO), offering specialized services to a wide range of clients across various industries.
Influx Healthtech, an Book Built Issue amounting to ₹ 58.57 Crores, consisting an Fresh Issue of 50.00 Lakh Shares worth ₹ 48.00 Crores and an Offer for Sale of 11.00 Lakh Shares totaling to ₹ 10.57 Crores. The subscription period for the Influx Healthtech IPO opens on June 18, 2025, and closes on June 20, 2025. The allotment is expected to be finalized on or about Monday, June 23, 2025, and the shares will be listed on the NSE SME with a tentative listing date set on or about Wednesday, June 25, 2025.
The Share Price Band of Influx Healthtech IPO is set at ₹ 91 to ₹ 96 per equity share. The Market Capitalisation of the Influx Healthtech Limited at IPO price of ₹ 96 per equity share will be ₹ 222.24 Crores. The lot size of the IPO is 1,200 shares. Retail investors are required to invest a minimum of ₹ 1,15,200, while the minimum investment for High-Net-Worth Individuals (HNIs) is 2 lots (2,400 shares), amounting to ₹ 2,30,400.
RAREVER FINANCIAL ADVISORS PRIVATE LIMITEDis the book running lead manager of the Influx Healthtech IPO, while MAASHITLA SECURITIES PRIVATE LIMITEDis the registrar for the issue. R.K. Stockholding Private Limitedis the Market Maker for Influx Healthtech IPO.
Influx Healthtech LimitedIPO GMP Today
The Grey Market Premium of Influx Healthtech Limited IPO is expected to be ₹ 11 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.
Influx Healthtech LimitedIPO Live Subscription Status Today: Real-Time Update
As of 07:00 PM on 20 June, 2025, the Influx Healthtech Limited IPO live subscription status shows that the IPO subscribed 187.32 times on Final Day of subscription period. Check the Influx Healthtech IPO Live Subscription Status Today at NSE.
Influx Healthtech IPO Anchor Investors Report
Influx Healthtech has raised ₹ 16.66 Crores from Anchor Investors at a price of ₹ 96 per shares in consultation of the Book Running Lead Managers. The company allocated 17,36,400 equity shares to the Anchor Investors. Check Full List of Influx Healthtech Anchor Investor List.
Note:- Equity Shares allotted to Anchor Investors (if any) are allotted from Qualified Institutional Buyers (QIBs) reservation portion. Note:- The Number of shares offered shown IPO subscription section table is calculated at the lower end of the price band and Number of shares calculated in IPO details table section is calculated at upper end of the price band in case of Book Building Issue, so there can be difference. This is because we assume shares will be issued by the company at upper band as Anchor Investors also subscribe at upper band and shares will be issued at lower band only if in case of undersubscription of IPO.
Note:- Market Maker portion (if any) are not shown separately in subscription table and included in NIIs reservation portion.
Influx Healthtech LimitedDay Wise IPO GMP Trend
Date
IPO Price
Expected Listing Price
GMP
Last Updated
12 June 2025
₹ 96
₹ 107
₹ 11 (10.56%)
07:00 PM; 12 June 2025
Influx Healthtech Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online Influx Healthtech IPO allotment date is 23 June, 2025, Monday. Influx Healthtech IPO Allotment will be out on 23rd June, 2025 and will be live on Registrar Website from the allotment date. Check Influx Healthtech IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Influx Healthtech Limited IPO from the dropdown list of IPOs
- Enter your application number, PAN, or DP Client ID
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.
Objectives of Influx Healthtech LimitedIPO
Influx Healthtech proposes to utilise the Net Proceeds towards the following objects: 1. ₹ 2,260.11 Lakhs is required for funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division; 2.₹ 1,158.58 Lakhs is required forfunding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division; 3. ₹ 275.65 Lakhs is required forpurchase of Machineries for Homecare and Cosmetic Division; and 4. General Corporate Purposes.
Influx Healthtech Limited, established in 2020 and based in Mumbai, is a healthcare-focused Contract Development and Manufacturing Organization (CDMO). The company provides specialized manufacturing services across various industries.
It operates three manufacturing facilities in Thane, Maharashtra, spanning 9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft., respectively. These facilities hold international certifications including GMP, HACCP, ISO 22000, and Halal, ensuring high standards of quality, safety, and regulatory compliance.
The company’s manufacturing capabilities cover Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms such as tablets, capsules, and injectables.
Key clients as of March 31, 2025, include Bling Brands Private Limited, Evoq Business Ventures LLP, HSHS Nutraceuticals Limited, Bruder Life Science, and Bigflex Lifescience Private Limited. The business is supported by advanced machinery, a dedicated quality control unit, and a skilled workforce. As of today, the company have a total workforce of 163 permanent employees on a payroll basis. The Banker to the Company is Axis Bank Limited.
INDUSTRY ANALYSIS
India’s Nutraceutical Industry
The global nutraceutical market is valued at approximately $400 billion, integrating food, pharmaceuticals, and biotechnology. While India’s share is under 2%, the country has significant potential, supported by a rich tradition in Ayurveda and growing innovation. The Council of Scientific and Industrial Research (CSIR) formed a Nutraceutical Sector Task Force in 2021, including members from key ministries such as Commerce, Pharmaceuticals, FSSAI, AYUSH, and Food Processing, to address industry challenges and standardize regulations.
Initiatives like the establishment of nutraceutical incubation hubs at institutions such as NIFTEM-Kundli, Centurion University, and AIC-CSIR-CCMB, along with the launch of India’s first government-backed Nutraceutical Centre of Excellence in Kerala, are fostering innovation and infrastructure. The collaboration between the Task Force and CBIC aims to streamline exports through a unique HSN code, positioning India for accelerated growth in global nutraceuticals.
Cosmetic and Household (FMCG) Industry
India’s FMCG sector continues to witness robust expansion, driven by consumer demand, price increases in essentials, and the resurgence of rural markets. The sector employs around 3 million people and accounts for 5% of India’s factory employment. In FY23, revenues grew 7–9%, while volume growth in Q1 FY24 reached 7.5%, the highest in eight quarters.
Key growth drivers include government policy support, digital commerce platforms, new product launches, and increasing disposable incomes. CRISIL forecasts a 7–9% revenue increase in FY25, supported by rural demand recovery and modern trade expansion. The FMCG sector, India’s fourth-largest, is projected to reach $615.87 billion by 2027, growing at a CAGR of 27.9%, with urban areas contributing 65% and rural India over 35%.
Ayurvedic Industry
Ayurveda, India’s ancient holistic health system, continues to remain relevant in modern healthcare. Rooted in the use of medicinal plants and herbs, Ayurveda emphasizes preventive care, natural healing, and balance of body, mind, and spirit. Its environmentally friendly, sustainable approach aligns with growing global interest in natural and personalized healthcare. As wellness and lifestyle diseases rise, Ayurveda's principles of holistic health are gaining traction both domestically and internationally.
Pet Food Industry
India’s pet food market was valued at $843.89 million in 2024, with projections indicating a rise to $1.98 billion by 2030, at a CAGR of 15.37%. Growth is driven by increased pet ownership, urbanization, and rising disposable incomes. Urban pet owners are prioritizing premium and nutritionally advanced pet food, leading to demand for specialized and organic products.
As per the State of Pet Homelessness report (May 2024), India has 69.3 million stray animals, down from 2021 levels, indicating progress in pet adoption and care. The shift towards natural, holistic pet nutrition is creating opportunities for niche brands and startups in the sector.
Conclusion:
India’s nutraceutical, FMCG, Ayurvedic, and pet food sectors are poised for strong growth, supported by policy backing, consumer awareness, and innovation hubs. These trends offer significant expansion opportunities for companies like Influx Healthtech operating in these domains.
BUSINESS STRENGTHS
1. Diversified Product Portfolio
Influx Healthtech manufactures a wide range of products, including multi-nutritional tablets, dietary supplements, Ayurvedic products, oral dispersible films, gummy candies, ice sticks, and other innovative formulations, catering to varied consumer needs across multiple segments.
2. Diverse Clientele
The client base spans sectors such as cosmetics, pharmaceuticals, and homecare, offering a strategic edge by reducing dependency on any single industry. This diversity enhances financial stability and supports operational resilience.
3. Stringent Quality Assurance/Quality Control
Quality is maintained through rigorous QC mechanisms implemented at every manufacturing stage. This ensures compliance with customer specifications and adherence to regulatory standards.
4. Formulation Development Expertise
A dedicated Formulation Development Department drives innovation across nutraceuticals, cosmetics, Ayurvedic, and veterinary product lines. The team ensures each formulation is market-ready, effective, and regulation-compliant.
BUSINESS STRATEGIES
Growth Strategy : Influx Healthtech Limited is focused on strengthening its Nutraceutical, Veterinary Food, Homecare, and Cosmetic divisions. The strategy includes expanding manufacturing facilities and investing in advanced machinery to meet rising market demand in these segments. Revenue from the Nutraceuticals segment grew from ₹71.61 crore in FY 2022-23 to ₹93.47 crore in FY 2023-24, and further to ₹94.04 crore in FY 2024-25, reflecting a growth of 30.52% and 0.61%, respectively.
BUSINESS RISK FACTORS & CONCERNS
1. High Dependence on the Nutraceutical Industry
A significant portion of revenue is generated from the nutraceutical segment. Any slowdown in this industry, loss of key clients, or shift towards in-house manufacturing could adversely impact operations. Competitive innovations in product development, raw materials, or pricing may also reduce market share and profitability. However, no material impact from these risks has been recorded in the last three financial years.
2. Single-Region Manufacturing Concentration
All manufacturing operations are located in Palghar, Thane, Maharashtra, making the company vulnerable to risks such as equipment failure, supply chain issues, natural disasters, security threats, or other operational disruptions. Lack of geographic diversification in production could hinder growth and continuity.
3. Revenue Concentration in Specific States
Major revenue contributions come from Maharashtra, Gujarat, and Karnataka, increasing exposure to region-specific economic, competitive, and regulatory risks. Expanding into new territories poses challenges due to local competition, unfamiliar regulations, and established regional players.
4. Absence of AYUSH License
The company does not currently hold an AYUSH license, which is not required under its current operations. However, future regulatory changes or business model expansion could bring the company under AYUSH jurisdiction, potentially leading to compliance costs, operational changes, or regulatory disputes, affecting financial and reputational stability.
Influx Healthtech faces key business risks related to industry concentration, geographic dependency, regulatory exposure, and competitive threats. These factors could potentially impact revenue stability, operational efficiency, and future growth.
Influx Healthtech Limited Financial Information (Restated Consolidated)
Amount in (₹ in Lakh)
Period Ended
Mar 31, 2025
Mar 31, 2024
Mar 31, 2023
Reserve of Surplus
1,815.00
2,275.44
1,162.65
Total Assets
7,029.91
4,110.31
2,830.42
Total Borrowings
21.92
32.48
79.85
Fixed Assets
1,872.50
1,370.60
629.64
Cash
191.06
360.56
354.71
Net Borrowing
-169.14
-328.08
-274.86
Revenue
10,498.67
10,001.60
7,605.65
EBITDA
2,070.45
1,700.65
1,072.34
PAT
1,336.60
1,112.80
719.63
EPS
7.36
6.13
3.96
Note 1:- RoE, ROCE & RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP. Note 2:- Pre EPS and Post EPS calculation in KPI is based (Profit/Loss for the Year) on 31st Mar, 2025 Data, given in RHP. Note 3:- RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP. Note 4:- Price to Book Value calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Lead Manager : RAREVER FINANCIAL ADVISORS PRIVATE LIMITED Contact Person : Mr. Richi M. Shah / Mr. Prerak P. Thakkar Telephone : 079-4925 8260/ +91-99981 23745 Email : ipo.influxhealth@rarever.in Website : https://www.rarever.in/
Influx Healthtech IPO Review
Influx Healthtech Limited is a Mumbai-based, healthcare focused company specialising in contract manufacturing. Since its inception in 2020, the company has established itself as a reliable Contract Development and Manufacturing Organization (CDMO), offering specialized services to a wide range of clients across various industries.
The company is led by Promoters, Mr. Munir Abdul Ganee Chandniwala who has approx. 22 years in the industry of Nutraceutical, Cosmetics, Ayurvedic and Homecare, Mrs. Shirin Munir Ahmed Chandniwala has more than 12 years of experience in the field of trading of packaging materials and Mr. Abdul Ganee Abdul Rasul Chandniwala has approximately 21 years of experience in the pharmaceutical industry.
The Revenues from operations for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 10,498.67 Lakh, ₹ 10,001.60 Lakh and ₹ 7,605.65 Lakh. The EBITDA for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 2,070.45 Lakh, ₹ 1,700.65 Lakh and ₹ 1,072.34 Lakh. The Profit after Tax for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 1,336.60 Lakh, ₹ 1,112.80 Lakh and ₹ 719.63 Lakh respectively. This indicates a steady growth in financial performance.
The Company Key Performance Indicates the pre-issue EPS of ₹7.36and post-issue EPS of ₹ 5.77 for FY24.The pre-issue P/E ratio is 13.04x, while the post-issue P/E ratio is 16.63x against the Industry P/E ratio is 29x. The company's ROCE for FY24 is 49.17%, ROE for FY24 is 36.98% and RoNW is 36.98%. These metrics suggest that the IPO is fairly priced.
The Grey Market Premium (GMP) of Influx Healthtech showing listing gains of 10.56 %.Given the company's financial performance and the valuation of the IPO, we recommend RiskyInvestors to Apply to the Influx Healthtech Limited IPO for Listing gain.
Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit our website abhayvarn.com
About the Author
CA Abhay Kumar (Also known as CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.
10,498.67 Lakh, ₹ 10,001.60 Lakh and ₹ 7,605.65 Lakh. The EBITDA for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 2,070.45 Lakh, ₹ 1,700.65 Lakh and ₹ 1,072.34 Lakh. The Profit after Tax for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 1,336.60 Lakh, ₹ 1,112.80 Lakh and ₹ 719.63 Lakh respectively. This indicates a steady growth in financial performance.
The Company Key Performance Indicates the pre-issue EPS of ₹7.36and post-issue EPS of ₹ 5.77 for FY24.The pre-issue P/E ratio is 13.04x, while the post-issue P/E ratio is 16.63x against the Industry P/E ratio is 29x. The company's ROCE for FY24 is 49.17%, ROE for FY24 is 36.98% and RoNW is 36.98%. These metrics suggest that the IPO is fairly priced.
The Grey Market Premium (GMP) of Influx Healthtech showing listing gains of 10.56 %.Given the company's financial performance and the valuation of the IPO, we recommend RiskyInvestors to Apply to the Influx Healthtech Limited IPO for Listing gain.
Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit our website abhayvarn.com
About the Author
CA Abhay Kumar (Also known as CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.
